Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo-Controlled Trial.

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

It is unclear if genetic variants affect smoking cessation treatment response.

The primary end point was biochemically verified 7-day point prevalence abstinence at the end of treatment (EOT, week 12).

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

In this genotype-stratified randomized, double-blind, placebo-controlled clinical trial (May 2015-August 2019 in St Louis, Missouri), smokers were randomized by genotype in blocks of six (1:1:1 ratio) to three conditions: 12 weeks of placebo (n = 273), combination nicotine patch and lozenge (combination nicotine replacement therapy, cNRT, n = 275), or varenicline (n = 274).

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Therapeutic nicotine (patch, non-peptide).

Some participants received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.

What Was Measured

The primary end point was biochemically verified 7-day point prevalence abstinence at the end of treatment (EOT, week 12).

The subject headings attached to it are Administration, Cutaneous, Missouri, Nerve Tissue Proteins, Nicotine, Nicotinic Agonists, Race Factors and Receptors, Nicotinic.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

The publication is from 2020 (Clinical pharmacology and therapeutics), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.